Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Place of /sup 57/Co-bleomycin scanning in the evaluation of tumors

Journal Article · · Am. J. Roentgenol.; (United States)
The clinical records and imaging studies of 140 patients who had /sup 57/Co-bleomycin scans were reviewed. In 53% of the patients with known tumor at the time of examination, all clinically demonstrable lesions picked up cobalt. The success rate was particularly high in carcinoma of the lung (15 of 17) and gastrointestinal tract (12 of 17). The major role of cobalt bleomycin seems to be as an early screening test for metastases in patients with carcinoma of the lung, gastrointestinal tract, and uterus. The scan is most useful in demonstrating spread to the brain, liver, and adrenals.
Research Organization:
New England Medical Center Hospital, Boston
OSTI ID:
5340617
Journal Information:
Am. J. Roentgenol.; (United States), Journal Name: Am. J. Roentgenol.; (United States) Vol. 129:2; ISSN AJROA
Country of Publication:
United States
Language:
English